nivolumab
BMS
['agent', 'biomarker', 'marker ']
 we learned and will learn a lot more from prosper. the idea of immune priming when the bulk of the ag is present needs further investigation. other agents? longer treatment duration? all 4 completed adj studies present an amazing opportunity for biomarker research.
Assistant Professor of Med Oncology @UWSMPH, GU focus. Med Director of Clin Ca Research Informatics @UWCarbone, Uni of Wisconsin.